Entera Bio (ENTX) Change in Cash (2021 - 2026)

Entera Bio (ENTX) has reported Change in Cash for 6 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.

• Quarterly Change in Cash fell 124.82% year-over-year to -$3.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.7 million (down 176.13% YoY) and the FY2025 annual result came in at $6.2 million, up 364.26% from the prior year.
• Change in Cash declined to -$3.0 million in Q1 2026 per ENTX's latest filing, from -$1.7 million in the prior quarter.
• Over the last five years, Change in Cash for ENTX reached as high as $11.9 million in Q1 2025 and fell as low as -$4.8 million in Q1 2022.
• A 5-year average of -$763941.2 and a median of -$1.7 million in 2025 frame the typical range for Change in Cash.
• The largest YoY upside for Change in Cash was 750.93% in 2025 against a maximum downside of 1337.82% in 2025.
• Year by year, Change in Cash stood at -$2.0 million in 2022, then soared by 269.27% to $3.4 million in 2023, then plunged by 48.75% to $1.7 million in 2024, then tumbled by 198.57% to -$1.7 million in 2025, then slumped by 71.89% to -$3.0 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$3.0 million, -$1.7 million, and -$2.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.